List All Sections And Required Content Of The Ema Maa

The European Medicines Agency (EMA) evaluates marketing authorization applications (MAA) for medicinal products in the EU, providing comprehensive information to assess Quality, Safety, and Efficacy. These applications require the submission of a dossier of documentation and can be submitted by any company, firm or non-profit organization. The application process involves a development process and may require further research. 8.5% of applications utilize registries, and the MAA can also be used in other markets.

The Marketing Authorization Application (MAA) submitted to the European Medicines Agency (EMA) typically consists of the following sections and required content:

  1. Administrative Information:

    • Applicant details, including company name, address, and contact information.
    • Details of the medicinal product, including its proposed name and form.
  2. Summary of Product Characteristics (SmPC):

    • A comprehensive summary of the product's properties and intended use, including indications, dosage and administration, contraindications, adverse reactions, and more.
  3. Quality Overall Summary (Chemistry, Manufacturing, and Controls - CMC):

    • Detailed summary providing an overview of the quality, manufacturing, and control aspects of the medicinal product.
  4. Nonclinical Overview and Summary:

    • Summary of the nonclinical pharmacology and toxicology studies conducted, including the overall conclusions and relevance to the product's safety and efficacy.
  5. Clinical Overview and Summary:

    • Summary of the clinical development program, including the key study designs, results, and conclusions regarding the safety and efficacy of the medicinal product.
  6. Risk Management Plan (RMP):

    • Detailed plan outlining the identification, characterization, and minimization of risks associated with the medicinal product.
  7. Pharmacovigilance System Master File (PSMF):

    • Description of the pharmacovigilance system, including its structure, responsibilities, and processes for monitoring the safety of the product once authorized.
  8. Product Information (Labelling):

    • Comprehensive documentation outlining the product's packaging, labeling, and patient information leaflet, ensuring accurate and clear information for patients and healthcare professionals.
  9. Expert Reports and Summary Documents:

    • Expert reports providing detailed analysis and evaluation of the product's characteristics, safety, and efficacy.
  10. Responses to Major Objections:

  • Include responses to any major objections raised by the regulatory authority, providing clarification and supporting evidence as necessary.

These sections and associated content form the core components of an EMA Marketing Authorization Application (MAA) dossier, providing the necessary information for the evaluation of the medicinal product's quality, safety, and efficacy. If you need further clarification or additional details on any specific section, feel free to ask!

Work fast from anywhere

Stay up to date and move work forward with BrutusAI on macOS/iOS/web & android. Download the app today.